CompanyIntravacc B.V.
Netherlands
Intravacc is the new governmental Institute working under the Dutch Ministry of Public Health, Welfare and Sport, responsible for the research and development activities in the field of translational vaccinology.
Private/Public:
public
Phone:+31 30 7920 300
Email:[email protected]
Website:https://www.intravacc.nl
Address:Antonie van Leeuwenhoeklaan 93721 MA Bilthoven , Netherlands
2012
Since
1
Country
6
Top Service Categories
75
Sub-Service Categories
Top Services
Analytical
Analytical Equipment
Analytical lab services
- Service Type
- CMC analytical- Protein/Peptide/DNA/Oligo
- Binding assays
- Biological QC testing (Cell-based assay)
- Electrophoresis (SDS-PAGE, IF, CE)
- Molecular weight determination
- Peptide/protein primary structure
- Protein aggregation/deaggregation
- Protein identification/characterization
- Protein secondary/tertiary structure
- Vaccine products testing/QC release
- Methods
- Test-Instrumental
- Tests - Physical
- CMC analytical- Protein/Peptide/DNA/Oligo
Discovery and Preclinical
Specific Services-Discovery
API/Biologicals Production
API/Biologics development and manufacturing
Bioanalytical
Bioanalytical assays
Research Supplies
Life Sciences Supplies/Reagents
Netherlands
- (13.Apr.2021) Intravacc Announces Positive Preclinical Data for Its OMV-based Lyme Vaccine
- (07.Apr.2021) Intravacc Announces Positive Preclinical Data for Its SARS-CoV-2 Nose Spray Vaccine
- (24.Mar.2021) Intravacc Announces Appointment of Nathalie Laarakker as Chief Financial Officer
- (19.Feb.2021) Dutch Intravacc Starts Concept Design for Multifunctional, High-Capacity Vaccine Plant for National Requirement
- (21.Jan.2021) Intravacc's Sabin Inactivated Polio Vaccine (SIPV), Outlicensed to LG Chem, Receives WHO Prequalification
- (19.Jan.2021) Intravacc Announces Completion of Formulation and Manufacturing Process Development of PRV-101 Vaccine Candidate for Provention Bio
- (08.Jan.2021) LG Chem Inks Contract with UNICEF to Supply Polio Vaccine 'Eupolio'
- (06.Jan.2021) Cristal Therapeutics and Intravacc Announce Strategic Collaboration to Advance Novel Vaccine Platforms
- (22.Dec.2020) Dutch Vaccine Developer Intravacc Becomes Public Shareholding Company Effective 1st January 2021
- (16.Nov.2020) Intravacc Publishes Positive Phase I Shigella Conjugate Vaccine Data
- (05.Nov.2020) Intravacc Appoints Prof. Dr. Virgil Schijns as Chief Scientific Officer
- (05.Oct.2020) Intravacc 2.0
- (08.Sep.2020) Intravacc Receives US NIH/NIAID Contract to Develop Enterovirus D68 Vaccine
- (25.Aug.2020) Intravacc and Therapyx Jointly Develop the World's First Prophylactic Gonorrhea Vaccine
- (18.Aug.2020) Intravacc's Candidate RSV Vaccine Demonstrates Safety in Phase I Trial
- (11.Aug.2020) Therapyx, Inc. Receives an NIH SBIR Phase IIb Grant in the Amount of $2.8 Million to Advance Its Mucosal Immunization Platform
- (29.Jul.2020) Intravacc and Celonic to Develop and Produce a Novel COVID-19 Vaccine
- (23.Jul.2020) Intravacc and Leiden University Developed an Animal Replacement Method for Vaccines
- (02.Jul.2020) Intravacc and CimCure Involved in the Joint Development of a COVID-19 Vaccine
- (01.Jul.2020) Intravacc to In-License CimCure's iBoost Technology, Expanding Its Vaccine Platform Portfolio
- (22.Jun.2020) Intranasal Immunization With Intravacc's Experimental Whooping Cough Vaccine Confers Broad Protection
- (08.Jun.2020) Intravacc and Versatope Sign Research Service Agreement to Develop Universal Influenza Vaccine Based on OMV Technology
- (04.Jun.2020) Intravacc Partners With Wageningen Bioveterinary Research and Utrecht University to Develop an Intranasal COVID-19 Vaccine
- (02.Jun.2020) Intravacc and EpiVax Team Up in Development of COVID-19 Emerging Vaccine
- (14.May.2020) Intravacc to Develop Emergency and Conventional COVID-19 Vaccines